Circulating tumor-derived biomarkers in lung cancer

Journal of Thoracic Disease

Volumn 4, Issue 5, 2012, Pages 448-449

  Taenzer, Aline ^a   Alix Panabières, Catherine ^b,c,d   Wikman, Harriet ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID; TUMOR MARKER;

BLOOD ANALYSIS; CANCER RESEARCH; CANCER SCREENING; CANCER STAGING; CELL ASSAY; CELL HOMING; CELL SPREADING; CIRCULATING TUMOR CELL; CLINICAL EVALUATION; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; HUMAN; LUNG CANCER; NOTE; OVERALL SURVIVAL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 84868271933     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.08.17     Document Type: Note

References (15)

1. Mok TS. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011; 8: 661-8.
2. Riethdorf S, Wikman H, Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008; 123: 1991-2006.
3. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-40.
4. O'Flaherty JD, Gray S, Richard D, et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 2012; 76: 19-25.
5. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011; 29: 1556-63.
6. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009; 15: 6980-6.
7. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30: 525-32.
8. Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol 2012; 7: 512-9.
9. Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 2012; 7: 306-15.
10. Lecharpentier A, Vielh P, Perez-Moreno P, et al. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 2011; 105: 1338-41.
11. Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012; 63: 199-215.
12. Zhang R, Shao F, Wu X, et al. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 2010; 69: 225-31.
13. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-77.
14. Wang Q, Wang S, Wang H, et al. MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment. Exp Biol Med (Maywood) 2012; 237: 227-35.
15. Roth C, Kasimir-Bauer S, Pantel K, et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 2011; 5: 281-91.